GANTRISIN
LOE ApproachingNDAORALSYRUP
Approved
Dec 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTRISIN is an oral syrup formulation approved by Roche in 1953 for treating bacterial infections. The drug represents a legacy small-molecule antibiotic from the sulfonamide class. Its exact mechanism and current indications are not fully detailed in available data.
LOE Approaching
As a 70-year-old product approaching loss of exclusivity with minimal linked job openings, this represents a declining asset with reduced commercial momentum and limited team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GANTRISIN offers limited career growth potential given its approaching loss of exclusivity and zero linked job openings. This role best suits professionals seeking stability in legacy portfolio stewardship or transition to higher-growth assets.
Product Manager (Legacy Portfolio)Supply Chain Manager
Worked on GANTRISIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.